cometadata/datacite-titles-descriptions-related-identifiers huggingface dataset:
DOI: 10.15156/bio/sh0203384.10fu
title: SH0203384.10FU

description: UNITE provides a unified way for delimiting, identifying, communicating, and working with DNA-based Species Hypotheses (SH). All fungal ITS sequences in the international nucleotide sequence databases are clustered to approximately the species level by applying a set of dynamic distance values (<0.5 - 3.0%). All species hypotheses are given a unique, stable name in the form of a DOI, and their taxonomic and ecological annotations are verified through distributed, web-based third-party annotation efforts. SHs are connected to a taxon name and its classification as far as possible (phylum, class, order, etc.) by taking into account identifications for all sequences in the SH. An automatically or manually designated sequence is chosen to represent each such SH. These sequences are released (https://unite.ut.ee/repository.php) for use by the scientific community in, for example, local sequence similarity searches and next-generation sequencing analysis pipelines. The system and the data are updated automatically as the number of public fungal ITS sequences grows.
DOI: 10.15156/bio/sh0203385.10fu
title: SH0203385.10FU

description: UNITE provides a unified way for delimiting, identifying, communicating, and working with DNA-based Species Hypotheses (SH). All fungal ITS sequences in the international nucleotide sequence databases are clustered to approximately the species level by applying a set of dynamic distance values (<0.5 - 3.0%). All species hypotheses are given a unique, stable name in the form of a DOI, and their taxonomic and ecological annotations are verified through distributed, web-based third-party annotation efforts. SHs are connected to a taxon name and its classification as far as possible (phylum, class, order, etc.) by taking into account identifications for all sequences in the SH. An automatically or manually designated sequence is chosen to represent each such SH. These sequences are released (https://unite.ut.ee/repository.php) for use by the scientific community in, for example, local sequence similarity searches and next-generation sequencing analysis pipelines. The system and the data are updated automatically as the number of public fungal ITS sequences grows.
DOI: 10.26023/7x7x-s9bc-4d12
title: NAVY NOGAPS Global Grids. Version 1.0

description: This dataset contains NAVY/NOGAPS global grid model data. The files are large. Each file contains 12 hours of data.
DOI: 10.15468/dl.69hpb9
title: Occurrence Download

description: A dataset containing 11307 species occurrences available in GBIF matching the query:
{
 "and" : [
 "Country is France",
 "TaxonKey is Valerianella dentata"
 ]
}

 The dataset includes 11307 records from 374 constituent datasets; see https://api.gbif.org/v1/occurrence/download/0042778-250920141307145/datasets/export for details.
 
Data from some individual datasets included in this download may be licensed under less restrictive terms.
DOI: 10.15468/dl.5jscky
title: Occurrence Download

description: A dataset containing 219 species occurrences available in GBIF matching the query:
{
 "and" : [
 "Geometry POLYGON((-7.21439 43.54061,-7.17511 43.54061,-7.17511 43.56909,-7.21439 43.56909,-7.21439 43.54061))",
 "HasCoordinate is true",
 "HasGeospatialIssue is false",
 "TaxonKey is Plantae",
 "Year 2015-2025"
 ]
}

 The dataset includes 219 records from 5 constituent datasets; see https://api.gbif.org/v1/occurrence/download/0042779-250920141307145/datasets/export for details.
 
Data from some individual datasets included in this download may be licensed under less restrictive terms.
DOI: 10.15468/dl.hhj5np
title: Occurrence Download

description: A dataset containing 64163 species occurrences available in GBIF matching the query:
{
 "and" : [
 "BasisOfRecord is Human Observation",
 "Geometry POLYGON((7.92534 50.21272,7.80897 42.82283,16.76992 42.35733,20.61033 38.98242,33.23714 42.70646,33.52808 53.704,7.92534 50.21272))",
 "OccurrenceStatus is Present",
 "TaxonKey is Sterna hirundo"
 ]
}

 The dataset includes 64163 records from 104 constituent datasets; see https://api.gbif.org/v1/occurrence/download/0042732-250920141307145/datasets/export for details.
 
Data from some individual datasets included in this download may be licensed under less restrictive terms.
DOI: 10.26023/z38e-rjg8-0b08
title: NOAA POES AMSU-A Data. Version 1.0

description: The NOAA POES AMSUA Data set is one of several satellite data sets collected by the University Corporation for Atmospheric Research/Joint Office for Science Support (UCAR/JOSS) as part of the EPIC project. Included in the data set are measurements from the Advanced Microwave Sounding Unit-A (AMSU-A) system aboard the National Oceanic and Atmospheric Administration (NOAA) Polar Orbiting Environmental Satellites (POES). The data cover the period from 7 September - 28 October 2001. Data are available at POES satellite overpass times. These data were acquired from the NOAA Satellite Active Archive (http://www.saa.noaa.gov) and are in level1B format.
DOI: 10.15468/dl.4vau5p
title: Occurrence Download

description: A dataset containing 7822 species occurrences available in GBIF matching the query:
{
 "and" : [
 "BasisOfRecord is Human Observation",
 "HasCoordinate is true",
 "HasGeospatialIssue is false",
 "Year is greater than or equal to 2016",
 "Geometry POLYGON ((16.96139 43.14916, 16.81111 43.16138, 16.66222 43.20027, 16.61333 43.21388, 16.56527 43.21805, 16.47582 43.21194, 16.45722 43.21027, 16.37778 43.19535, 16.43055 43.16945, 16.46472 43.16028, 16.53388 43.14361, 16.65417 43.11972, 16.66611 43.11916, 16.87972 43.12056, 17.05778 43.1125, 17.11 43.11638, 17.11639 43.13611, 16.96139 43.14916))"
 ]
}

 The dataset includes 7822 records from 10 constituent datasets; see https://api.gbif.org/v1/occurrence/download/0042780-250920141307145/datasets/export for details.
 
Data from some individual datasets included in this download may be licensed under less restrictive terms.
DOI: 10.6084/m9.figshare.29476686
title: Safety and efficacy of immune checkpoint inhibitors in patients with cancer and hepatitis B: multicentre experience in a low-middle-income country

description: Immune checkpoint inhibitors (ICIs) are widely used in clinical practice. The primary objective of this study is to evaluate the safety and efficacy of ICIs in patients diagnosed with cancer who also have chronic hepatitis B virus (HBV) infection We reviewed the charts of patients who received an ICI between 2016 and 2023 at three tertiary cancer centers. We included those who had known chronic HBV infection. Of the 1352 patients screened, we identified 65 (4.8%) with concurrent hepatitis B. Of the 65 patients, 8 (12.3%) experienced irAEs (immune-related adverse events) of any grade, with 1 (1.5%) having grade 3 pneumonitis. No cases of reactivation were seen except for one patient (1.5%) with poor compliance with his antiviral drug developed hepatitis B reactivation 9 months after discontinuation of ICI. ICIs appear safe in patients with chronic hepatitis B, especially when antiviral treatment is given. We believe these patients should not be deprived of the potential benefits of ICIs solely because of chronic viral infection, neither in daily practice nor in clinical trials.
DOI: 10.6084/m9.figshare.29476686.v2
title: Safety and efficacy of immune checkpoint inhibitors in patients with cancer and hepatitis B: multicentre experience in a low-middle-income country

description: Immune checkpoint inhibitors (ICIs) are widely used in clinical practice. The primary objective of this study is to evaluate the safety and efficacy of ICIs in patients diagnosed with cancer who also have chronic hepatitis B virus (HBV) infection We reviewed the charts of patients who received an ICI between 2016 and 2023 at three tertiary cancer centers. We included those who had known chronic HBV infection. Of the 1352 patients screened, we identified 65 (4.8%) with concurrent hepatitis B. Of the 65 patients, 8 (12.3%) experienced irAEs (immune-related adverse events) of any grade, with 1 (1.5%) having grade 3 pneumonitis. No cases of reactivation were seen except for one patient (1.5%) with poor compliance with his antiviral drug developed hepatitis B reactivation 9 months after discontinuation of ICI. ICIs appear safe in patients with chronic hepatitis B, especially when antiviral treatment is given. We believe these patients should not be deprived of the potential benefits of ICIs solely because of chronic viral infection, neither in daily practice nor in clinical trials.
DOI: 10.15468/dl.j5fdvx
title: Occurrence Download

description: A dataset containing 6415116 species occurrences available in GBIF matching the query:
{
 "and" : [
 "Country is United Kingdom of Great Britain and Northern Ireland",
 "HasCoordinate is true",
 "Year is 2020"
 ]
}

 The dataset includes 6415116 records from 348 constituent datasets; see https://api.gbif.org/v1/occurrence/download/0042689-250920141307145/datasets/export for details.
 
Data from some individual datasets included in this download may be licensed under less restrictive terms.
DOI: 10.6084/m9.figshare.29476686.v1
title: Safety and efficacy of immune checkpoint inhibitors in patients with cancer and hepatitis B: multicentre experience in a low-middle-income country

description: Immune checkpoint inhibitors (ICIs) are widely used in clinical practice. The primary objective of this study is to evaluate the safety and efficacy of ICIs in patients diagnosed with cancer who also have chronic hepatitis B virus (HBV) infection We reviewed the charts of patients who received an ICI between 2016 and 2023 at three tertiary cancer centers. We included those who had known chronic HBV infection. Of the 1352 patients screened, we identified 65 (4.8%) with concurrent hepatitis B. Of the 65 patients, 8 (12.3%) experienced irAEs (immune-related adverse events) of any grade, with 1 (1.5%) having grade 3 pneumonitis. No cases of reactivation were seen except for one patient (1.5%) with poor compliance with his antiviral drug developed hepatitis B reactivation 9 months after discontinuation of ICI. ICIs appear safe in patients with chronic hepatitis B, especially when antiviral treatment is given. We believe these patients should not be deprived of the potential benefits of ICIs solely because of chronic viral infection, neither in daily practice nor in clinical trials.
DOI: 10.15468/dl.kbhdn6
title: Occurrence Download

description: A dataset containing 112 species occurrences available in GBIF matching the query:
{
 "and" : [
 "TaxonKey is Micromys minutus",
 "Country is Norway",
 "HasCoordinate is true"
 ]
}

 The dataset includes 112 records from 5 constituent datasets; see https://api.gbif.org/v1/occurrence/download/0042783-250920141307145/datasets/export for details.
 
Data from some individual datasets included in this download may be licensed under less restrictive terms.
DOI: 10.6084/m9.figshare.29608309
title: Robot-assisted medication management in home care and long-term care settings: a mixed-method systematic review

description: Medication errors and non-adherence in older adults are major issues linked to polypharmacy, cognitive decline, and caregiver burden. Medication management robots offer promise in improving patient care but require thorough evaluation . This review synthesizes the experiences of patients and caregivers, assesses the effectiveness of MMR in enhancing medication safety and minimizing errors, and offers insights into its broader implications for elderly home care. A mixed-methods systematic review was conducted using PRISMA guidelines. Searches were performed across six databases – PubMed, Scopus, Web of Science, Embase, CINAHL, and ProQuest – without publication date limits. Studies were appraised using the Mixed Methods Appraisal Tool (MMAT), and findings were synthesized through a convergent approach. Six studies (3 qualitative, 2 quantitative, 1 mixed-methods) from Sweden, Finland, and the U.S.A. were included. MMRs improved adherence, reduced medication errors, enhanced coordination among healthcare providers, and supported patient autonomy. Key challenges involved technical issues, such as incompatibility with liquid medications, concerns about privacy, and reluctance from users due to diminished human contact. MMRs show promise in elderly care, but successful adoption depends on structured training, ethical safeguards, and user-centered design. Further research is required to validate their long-term impact and optimize implementation strategies. The protocol for this review was registered with PROSPERO (registration number: CRD42024611310): https://www.crd.york.ac.uk/PROSPERO/view/CRD42024611310. This review looked at how medication management robot (MMR) systems can help older adults manage their medications at home and in long-term care. It helped understand how patients and caregivers experience these robots, how well they work in improving medication safety, and what their broader effects are on elderly care. We reviewed studies from several databases and included six studies. These studies showed that MMR systems can help make medication management safer by automatically dispensing the correct doses and reducing the workload for caregivers. They also allow older adults to manage their own medications more independently. However, to work well, proper training is necessary, and concerns such as technical, ethical, privacy, and accessibility need to be addressed. While MMR shows promise, more research is needed to develop systems that fit the needs of older adults.
DOI: 10.6084/m9.figshare.29608309.v2
title: Robot-assisted medication management in home care and long-term care settings: a mixed-method systematic review

description: Medication errors and non-adherence in older adults are major issues linked to polypharmacy, cognitive decline, and caregiver burden. Medication management robots offer promise in improving patient care but require thorough evaluation . This review synthesizes the experiences of patients and caregivers, assesses the effectiveness of MMR in enhancing medication safety and minimizing errors, and offers insights into its broader implications for elderly home care. A mixed-methods systematic review was conducted using PRISMA guidelines. Searches were performed across six databases – PubMed, Scopus, Web of Science, Embase, CINAHL, and ProQuest – without publication date limits. Studies were appraised using the Mixed Methods Appraisal Tool (MMAT), and findings were synthesized through a convergent approach. Six studies (3 qualitative, 2 quantitative, 1 mixed-methods) from Sweden, Finland, and the U.S.A. were included. MMRs improved adherence, reduced medication errors, enhanced coordination among healthcare providers, and supported patient autonomy. Key challenges involved technical issues, such as incompatibility with liquid medications, concerns about privacy, and reluctance from users due to diminished human contact. MMRs show promise in elderly care, but successful adoption depends on structured training, ethical safeguards, and user-centered design. Further research is required to validate their long-term impact and optimize implementation strategies. The protocol for this review was registered with PROSPERO (registration number: CRD42024611310): https://www.crd.york.ac.uk/PROSPERO/view/CRD42024611310. This review looked at how medication management robot (MMR) systems can help older adults manage their medications at home and in long-term care. It helped understand how patients and caregivers experience these robots, how well they work in improving medication safety, and what their broader effects are on elderly care. We reviewed studies from several databases and included six studies. These studies showed that MMR systems can help make medication management safer by automatically dispensing the correct doses and reducing the workload for caregivers. They also allow older adults to manage their own medications more independently. However, to work well, proper training is necessary, and concerns such as technical, ethical, privacy, and accessibility need to be addressed. While MMR shows promise, more research is needed to develop systems that fit the needs of older adults.
DOI: 10.6084/m9.figshare.29608309.v1
title: Robot-assisted medication management in home care and long-term care settings: a mixed-Method systematic review

description: Medication errors and non-adherence among older adults in home and long-term care settings are significant concerns driven by factors such as polypharmacy, cognitive decline, and caregiver burden. Emerging technologies, such as medication management robots (MMRs), present promising solutions but necessitate rigorous, systematic evaluation. This review synthesizes the experiences of patients and caregivers, assesses the effectiveness of MMR in enhancing medication safety and minimizing errors, and offers insights into its broader implications for elderly home care. A mixed-methods systematic review was conducted using PRISMA guidelines. Searches were performed across six databases – PubMed, Scopus, Web of Science, Embase, CINAHL, and ProQuest – without publication date limits. Studies were appraised using the Mixed Methods Appraisal Tool (MMAT), and findings were synthesized through a convergent approach. Six studies (3 qualitative, 2 quantitative, 1 mixed-methods) from Sweden, Finland, and the U.S.A. were included. MMRs improved adherence, reduced medication errors, enhanced coordination among healthcare providers, and supported patient autonomy. Key challenges involved technical issues, such as incompatibility with liquid medications, concerns about privacy, and reluctance from users due to diminished human contact. MMRs show promise in elderly care, but successful adoption depends on structured training, ethical safeguards, and user-centered design. Further research is required to validate their long-term impact and optimize implementation strategies. The protocol for this review was registered with PROSPERO (registration number: CRD42024611310): https://www.crd.york.ac.uk/PROSPERO/view/CRD42024611310. This review looked at how medication management robot (MMR) systems can help older adults manage their medications at home and in long-term care. It helped understand how patients and caregivers experience these robots, how well they work in improving medication safety, and what their broader effects are on elderly care. We reviewed studies from several databases and included six studies. These studies showed that MMR systems can help make medication management safer by automatically dispensing the correct doses and reducing the workload for caregivers. They also allow older adults to manage their own medications more independently. However, to work well, proper training is necessary, and concerns such as technical, ethical, privacy, and accessibility need to be addressed. While MMR shows promise, more research is needed to develop systems that fit the needs of older adults.
DOI: 10.6084/m9.figshare.29715583
title: Intersectoral costs of pneumococcal diseases: a systematic review of partial economic evaluation studies

description: This systematic review explores the intersectoral costs associated with pneumococcal diseases across different age groups and related impacts on societal costs. Four databases were searched (1990–2023) for partial economic evaluation studies of pneumococcal diseases from a societal perspective. The identified intersectoral costs were presented narratively and in tabular form. Studies were appraised on quality, and the PRISMA guidelines were followed. Twenty-four studies were included with wide variation in types of analysis. Intersectoral costs were captured in five sectors: patient/family, paid labor, opportunity costs, education, and public/social services. Paid labor was the main sector considered in the included studies, followed by patient/family. Cost bearers varied according to patients’ age group. Mean annual costs per child varied from $182 to $82,217 healthcare costs, $240 to $846 patient/family costs and $654 to $25,721 productivity cost. In adults, mean annual costs of $168 to $43,676 healthcare costs, and $23 to $33,149 productivity costs were reported. Intersectoral costs associated with pneumococcal diseases vary widely and appear in several sectors. More cost-of-illness studies are needed with wider perspectives, particularly in developing countries, to understand true economic costs of pneumococcal diseases and support the endeavor of informing a decision on treatment/preventive strategies. PROSPERO (CRD42023417042).
DOI: 10.6084/m9.figshare.29715583.v2
title: Intersectoral costs of pneumococcal diseases: a systematic review of partial economic evaluation studies

description: This systematic review explores the intersectoral costs associated with pneumococcal diseases across different age groups and related impacts on societal costs. Four databases were searched (1990–2023) for partial economic evaluation studies of pneumococcal diseases from a societal perspective. The identified intersectoral costs were presented narratively and in tabular form. Studies were appraised on quality, and the PRISMA guidelines were followed. Twenty-four studies were included with wide variation in types of analysis. Intersectoral costs were captured in five sectors: patient/family, paid labor, opportunity costs, education, and public/social services. Paid labor was the main sector considered in the included studies, followed by patient/family. Cost bearers varied according to patients’ age group. Mean annual costs per child varied from $182 to $82,217 healthcare costs, $240 to $846 patient/family costs and $654 to $25,721 productivity cost. In adults, mean annual costs of $168 to $43,676 healthcare costs, and $23 to $33,149 productivity costs were reported. Intersectoral costs associated with pneumococcal diseases vary widely and appear in several sectors. More cost-of-illness studies are needed with wider perspectives, particularly in developing countries, to understand true economic costs of pneumococcal diseases and support the endeavor of informing a decision on treatment/preventive strategies. PROSPERO (CRD42023417042).
DOI: 10.6084/m9.figshare.29715583.v1
title: Intersectoral costs of pneumococcal diseases: a systematic review of partial economic evaluation studies

description: This systematic review explores the intersectoral costs associated with pneumococcal diseases across different age groups and related impacts on societal costs. Four databases were searched (1990-2023) for partial economic evaluation studies of pneumococcal diseases from a societal perspective. The identified intersectoral costs were presented narratively and in tabular form. Studies were appraised on quality, and the PRISMA guidelines were followed. Twenty-four studies were included with wide variation in types of analysis. Intersectoral costs were captured in five sectors: patient/family, paid labor, opportunity costs, education, and public/social services. Paid labor was the main sector considered in the included studies, followed by patient/family. Cost bearers varied according to patients’ age group. Mean annual costs per child varied from $182 to $82,217 healthcare costs, $240 to $846 patient/family costs and $654 to $25,721 productivity cost. In adults, mean annual costs of $168 to $43,676 healthcare costs, and $23 to $33,149 productivity costs were reported. Intersectoral costs associated with pneumococcal diseases vary widely and appear in several sectors. More cost-of-illness studies are needed with wider perspectives, particularly in developing countries, to understand true economic costs of pneumococcal diseases and support the endeavor of informing a decision on treatment/preventive strategies. PROSPERO (CRD42023417042)